

Philip J Lowe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9132121/publications.pdf>

Version: 2024-02-01

37
papers

2,538
citations

304743

22
h-index

377865

34
g-index

38
all docs

38
docs citations

38
times ranked

2652
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2021, 48, 295-303. | 1.8 | 1 |
| 2 | Ligelizumab treatment for severe asthma: learnings from the clinical development programme. <i>Clinical and Translational Immunology</i> , 2021, 10, e1255. | 3.8 | 25 |
| 3 | Utility of food pellets containing 1-aminobenzotriazole for longer term <i>in vivo</i> inhibition of cytochrome P450 in mice. <i>Xenobiotica</i> , 2019, 49, 13-21. | 1.1 | 0 |
| 4 | Two Case Studies on How Study Designs Can Be Made More Informative Using Modeling and Simulation Approaches. <i>Clinical Pharmacology and Therapeutics</i> , 2017, 102, 908-911. | 4.7 | 1 |
| 5 | Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1051-1059. | 2.9 | 122 |
| 6 | Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion. <i>Drug Metabolism and Pharmacokinetics</i> , 2016, 31, 173-184. | 2.2 | 14 |
| 7 | Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. <i>Regulatory Toxicology and Pharmacology</i> , 2015, 71, 68-77. | 2.7 | 31 |
| 8 | Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. <i>MAbs</i> , 2015, 7, 829-837. | 5.2 | 13 |
| 9 | Pharmacokinetics, pharmacodynamics and safety of QGE031 (ligelizumab), a novel high-affinity anti-IgE antibody, in atopic subjects. <i>Clinical and Experimental Allergy</i> , 2014, 44, 1371-1385. | 2.9 | 216 |
| 10 | Omalizumab in Asthma: An Update on Recent Developments. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 525-536.e1. | 3.8 | 179 |
| 11 | Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies. <i>AAPS Journal</i> , 2014, 16, 810-842. | 4.4 | 9 |
| 12 | Visualization and Communication of Pharmacometric Models With Berkeley Madonna. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2014, 3, 1-20. | 2.5 | 33 |
| 13 | Population Pharmacokinetic and Pharmacodynamic Model-Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575. <i>Journal of Clinical Pharmacology</i> , 2012, 52, 1624-1644. | 2.0 | 34 |
| 14 | Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1 ^β Monoclonal Antibody. <i>Clinical Pharmacokinetics</i> , 2012, 51, e1-e18. | 3.5 | 151 |
| 15 | Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 46, 547-552. | 2.4 | 140 |
| 16 | Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 306-320. | 2.4 | 113 |
| 17 | From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics. <i>AAPS Journal</i> , 2011, 13, 169-178. | 4.4 | 26 |
| 18 | On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2010, 106, 195-209. | 2.5 | 73 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development. <i>Clinical Pharmacology and Therapeutics</i> , 2010, 87, 492-496. | 4.7 | 11 |
| 20 | Population Modeling of Filgrastim PK&PD in Healthy Adults Following Intravenous and Subcutaneous Administrations. <i>Journal of Clinical Pharmacology</i> , 2010, 50, 101S-112S. | 2.0 | 45 |
| 21 | In vivo regulation of interleukin 1 ^β in patients with cryopyrin-associated periodic syndromes. <i>Journal of Experimental Medicine</i> , 2009, 206, 1029-1036. | 8.5 | 270 |
| 22 | Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 61-76. | 2.4 | 146 |
| 23 | Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 107-113.e3. | 2.9 | 123 |
| 24 | Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations. <i>Clinical Pharmacokinetics</i> , 2009, 48, 817-826. | 3.5 | 23 |
| 25 | New Approach To Measure Protein Binding Based on a Parallel Artificial Membrane Assay and Human Serum Albumin. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 2009-2017. | 6.4 | 55 |
| 26 | On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. <i>Xenobiotica</i> , 2007, 37, 1331-1354. | 1.1 | 82 |
| 27 | A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. <i>British Journal of Clinical Pharmacology</i> , 2007, 63, 548-561. | 2.4 | 163 |
| 28 | Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1480-1487. | 3.3 | 125 |
| 29 | On the Prediction of the Human Response: A Recycled Mechanistic Pharmacokinetic/Pharmacodynamic Approach. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2005, 96, 182-192. | 2.5 | 96 |
| 30 | <title>Uptake of zinc(II)-phthalocyanine by HepG2 cells expressing the low-density lipoprotein receptor: studies with the liposomal formulation CGP55847</title>., 1994, , . | | 8 |
| 31 | BREAKDOWN OF HEPATIC TIGHT JUNCTIONS DURING REOXYGENATION INJURY. <i>Transplantation</i> , 1992, 53, 1211-1214. | 1.0 | 6 |
| 32 | Effect of molecular charge on para- and transcellular access of horseradish peroxidase into rat bile. <i>Hepatology</i> , 1989, 9, 866-871. | 7.3 | 19 |
| 33 | Output of proteins in bile by isolated perfused rat livers. <i>Biochemical Society Transactions</i> , 1982, 10, 222-222. | 3.4 | 0 |
| 34 | Fluorescence anisotropy from diphenylhexatriene in rat liver plasma membranes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1982, 689, 403-409. | 2.6 | 17 |
| 35 | Membrane fluidity and bile salt damage. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1981, 640, 55-65. | 2.6 | 62 |
| 36 | Membrane damage caused by bile salts. <i>Biochemical Society Transactions</i> , 1980, 8, 126-127. | 3.4 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Membrane lipid composition and susceptibility to bile salt damage. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1980, 599, 294-300. | 2.6 | 99 |